Skip to Main Content

Top of the morning to you, and a fine one it is here in Boston, where we are close to wrapping our latest trip to the corporate offices. We look forward to returning to the Pharmalot campus, of course, but meanwhile, we are as busy as ever foraging for interesting items. The task is made easier, though, thanks to some cups of stimulation. No surprise, right? As always, here are some tidbits. Have a successful day and do keep in touch …

Allergan is beginning an aggressive sales campaign for Kybella, the first injectable treatment for what doctors call “submental fat” in your jowls, Bloomberg News says. The drug maker, which spent $2.1 billion last year to acquire the treatment, plans to start the advertising blitz in September. The treatment involves up to 30 tiny injections that must avoid nerves and blood vessels running under the jawline.

A shareholder advisory firm says AstraZeneca shareholders should oppose the pay package for chief executive officer Pascal Soriot because his compensation is excessive and bonus targets were not disclosed, Bloomberg News tells us. His bonus and long-term incentives were 580 percent of his salary, according to Pensions & Investment Research Consultants. His annual bonus was not disclosed because it is considered commercially sensitive information.


Christi Shaw, who has run Novartis Pharmaceuticals, the US unit of the drug maker, for the past two years, is leaving for personal reasons, the company says. The job will now be divided between Fabrice Chouraqui and Tom Kendris, who is also general counsel. Meanwhile, Novartis reported net income fell due to lower sales of its Gleevec cancer drug, and its new Entresto heart failure drug and its Alcon eye care business continue to struggle, Reuters reports.

The World Health Organization removed two pharmaceutical ingredients supplied by Anuh Pharma from its list of pre-qualified ingredients and plans to inspect the company’s facility in Boisar, India, InPharma Technologist writes.


Sanofi’s dengue vaccine is being fast-tracked by Singapore’s Health Sciences Authority, which hopes to make an approval decision in six months instead of the usual nine months, Channel NewsAsia says.

Swiss Pharma International challenged three patents for formulating and preparing Biogen’s Tysabri multiple sclerosis drug by filing inter partes review petitions with the US Patent and Trademark Office, BioCentury writes.

Novo Nordisk is spending about $110 million to expand a facility in France that makes insulin and add 250 jobs, according to InPharma Technologist.

BioMarin Pharmaceutical stock soared Wednesday after reporting strong early-stage trial results for its hemophilia A treatment, Investor’s Business Daily reports.

The US Supreme Court heard arguments earlier this week about the scope of liability risk companies face involving allegations of violating the False Claims Act, Corporate Counsel tells us.

Biocon is recalling 5,505 bottles of its 5-milligram Simvastatin cholesterol-lowering tablets from the US for being sub-potent, according to The Economic Times.

AbbVie signed a deal worth up to $685 million with Argenx to develop and commercialize a preclinical human antibody program focused on an immuno-oncology target, Pharma Times says.

Basilea Pharmaceutica won a $100 million US government contract to support Phase 3 trials of an antibiotic that is is already being marketed in Europe as Zevtera, Reuters writes.

Comments are closed.